Notice Regarding Acquisition of Shares (Subsidiarization) of a Company Succeeding Part of the Pharmaceutical Manufacturing Business of Fuji Pharma Co., Ltd.

Overview of M&A

Nippon Kayaku Co., Ltd. resolved to acquire all shares of a newly established company succeeding part of Fuji Pharma Co., Ltd.'s pharmaceutical manufacturing business and convert it into a subsidiary, and concluded a share transfer agreement. The targeted business mainly involves contract development and manufacturing of prescription pharmaceuticals (injectables) at the Toyama Second Factory, scheduled to be succeeded through an absorption-type company split on October 1, 2026. The new company’s sales are approximately 3 billion yen (forecast for fiscal year ending March 2026), with capital of 1 million yen and 5,000 shares issued.

Future Outlook and Impact

The impact on consolidated financial results for the fiscal year ending March 2026 from this share acquisition is expected to be minimal. However, in the medium to long term, strengthening the stable supply system and expanding production capacity for anticancer drugs and biosimilars is expected to contribute to business growth and enhanced corporate value. The board resolution and share transfer agreement conclusion date is March 30, 2026; the new company establishment date is April 30, 2026; and the share transfer date is scheduled for October 1, 2026.